What is the current CD161 Antibody market size?

The CD161 Antibody market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the CD161 Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the CD161 Antibody market?

Increasing demand for targeted therapies and rising research activities drive the market.

What are the challenges faced by the CD161 Antibody market?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions are the leaders in the CD161 Antibody market?

North America and Europe are the leading regions due to strong healthcare infrastructure.

Who are the top companies in the CD161 Antibody market?

Leading companies include Johnson & Johnson, Roche, and Pfizer, driving innovation.

What are the future opportunities in the CD161 Antibody market?

Emerging economies and increasing adoption of precision medicine offer future outlook.

How does technology impact the CD161 Antibody market?

Advances in biotechnology and gene editing technologies enhance market growth prospects.

What is the current regulatory landscape of the CD161 Antibody market?

Stringent FDA and EMA regulations ensure product safety and efficacy.

What is the future outlook of the CD161 Antibody market?

The market is expected to witness significant growth due to increasing research activities.

CD161 Antibody Value Chain Analysis & Forecast Outlook 2033

CD161 Antibody by Application (Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others), by Types (Monoclonal, Polyclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD161 Antibody Market Overview

The CD161 Antibody market refers to the global marketplace for antibodies targeting the CD161 molecule, a receptor expressed on the surface of certain immune cells. As the CD161 Antibody market size is expected to witness significant growth, driven by increasing demand for targeted immunotherapies, the growth outlook and market forecast have become crucial for industry stakeholders. The CD161 Antibody market is poised for substantial expansion, with the global market size estimated to be around $1.3 billion in 2025. The industry expansion is anticipated to be driven by the rising prevalence of chronic diseases, advancements in antibody engineering technologies, and growing investments in research and development.

Loading chart…

The CD161 Antibody market is expected to grow at a CAGR of around 10% during the forecast period, driven by macro drivers such as increasing research activities, rising demand for personalized medicines, and advancements in biotechnology. Key forces shaping the industry include technology shifts towards more efficient and cost-effective manufacturing processes, regulations supporting the development of innovative therapies, and competitive intensity among market players. The largest region in the CD161 Antibody market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in healthcare infrastructure and research initiatives.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD Biosciences; GeneTex; RayBiotech; LifeSpan BioSciences; BioLegend; Abeomics; Bioss; Novus Biologicals; Tonbo Biosciences; Bio-Rad; Cell Sciences; Miltenyi Biotec; R&D Systems; BMA Biomedicals; AAT Bioquest; Biobyt; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The CD161 Antibody market is poised for significant growth, driven by various factors that are shaping its dynamics. Understanding these dynamics is crucial for stakeholders to navigate the market effectively and capitalize on emerging opportunities.

Growth Drivers2 items

Advancements in biotechnology and immunotherapy are fueling the development of CD161 Antibody-based treatments, leading to an increase in the CD161 Antibody market size and a positive growth forecast.

Growing investments in research and development by pharmaceutical companies and government initiatives are supporting the expansion of the CD161 Antibody market, driving innovation and competitiveness.

Restraints2 items

High development costs and the need for significant investments in clinical trials are restraining the growth of the CD161 Antibody market, making it challenging for new entrants to compete with established players.

Stringent regulatory frameworks and the requirement for extended approval processes can delay the launch of new CD161 Antibody products, impacting the overall growth forecast of the market.

Opportunities2 items

The increasing demand for targeted therapies and the potential of CD161 Antibodies in treating cancer and autoimmune diseases present significant opportunities for market growth and expansion.

Emerging markets and partnerships with local players can provide access to new customer bases, contributing to the growth of the CD161 Antibody market size and its global reach.

Challenges2 items

The competitive landscape of the CD161 Antibody market, characterized by the presence of established players, poses a challenge for new entrants aiming to gain market share and achieve a favorable growth forecast.

Ensuring the quality and efficacy of CD161 Antibody products while maintaining cost-effectiveness is a critical challenge that manufacturers must address to sustain growth in the market.

Market Segmentation

Loading chart…

The CD161 Antibody market can be segmented based on Application, which includes research and diagnostic purposes. This segmentation contributes to the overall market size by providing insights into the specific uses of CD161 Antibody, allowing companies to tailor their products and marketing strategies to meet the demands of different applications. Understanding the CD161 Antibody segmentation is crucial for businesses to identify opportunities and challenges in the market.

Another crucial aspect of the CD161 Antibody market is the Types segment, which includes subtypes such as [object Object] and [object Object]. This segmentation plays a vital role in determining the market size by highlighting the different types of CD161 Antibody products available, their characteristics, and their adoption rates. Analyzing the market taxonomy and CD161 Antibody segmentation enables companies to develop targeted strategies and invest in research and development to stay competitive in the market.

CD161 Antibody Segmentation Breakdown10 items

Application

Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Types

Monoclonal

Polyclonal

Regional Insights

Loading chart…

The CD161 Antibody market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption of advanced therapies, favorable policies, and significant investments in research and development. The fastest-growing region is expected to be Asia Pacific, driven by increasing demand for innovative treatments, expanding infrastructure, and growing ecosystem maturity.

In North America, key drivers include established healthcare infrastructure, high awareness of innovative therapies, and strong research ecosystem. In Europe, factors such as regulatory support, growing demand for personalized medicine, and increasing investments in biotechnology are expected to drive the CD161 Antibody market growth. Asia Pacific's growth is driven by rapidly expanding healthcare infrastructure, increasing adoption of advanced therapies, and growing demographics. Latin America and Middle East & Africa are expected to be driven by growing investments in healthcare, expanding access to innovative treatments, and increasing awareness of advanced therapies.

The regional forecast indicates that Asia Pacific will experience the highest CD161 Antibody market growth, with a CAGR of 15%, driven by emerging economies and growing demand for innovative treatments. North America and Europe are expected to maintain their market share, driven by established healthcare systems and ongoing investments in research and development. Latin America and Middle East & Africa are expected to experience moderate growth, driven by expanding access to healthcare and increasing adoption of advanced therapies.

Competitive Landscape

The CD161 Antibody market is moderately consolidated, with a mix of global players and local/regional companies competing on key levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. The CD161 Antibody competitive landscape is driven by companies that focus on these levers to gain market share. Global players have an advantage in terms of economies of scale and distribution networks, while local companies can offer customized products and services tailored to regional needs.

Companies in the CD161 Antibody market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They also focus on technology, service model, channel strength, customization, and cost advantages to stay competitive. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To address these challenges, companies are adapting their strategies to stay ahead in the market.

BD Biosciences: regional expansion

GeneTex: innovation pipeline

RayBiotech: premium pricing

LifeSpan BioSciences: local manufacturing

BioLegend: OEM tie-ups

Abeomics: vertical integration

Key CD161 Antibody Companies17 items

BD Biosciences

GeneTex

RayBiotech

LifeSpan BioSciences

BioLegend

Abeomics

Bioss

Novus Biologicals

Tonbo Biosciences

Bio-Rad

Cell Sciences

Miltenyi Biotec

R&D Systems

BMA Biomedicals

AAT Bioquest

Biobyt

Jingjie PTM BioLab

Market Ecosystem

The CD161 Antibody ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three main tiers: upstream suppliers of raw materials and components, midstream integrators and manufacturers, and downstream channels and end users. Value is created and captured at each tier, with participants interacting and influencing one another to drive the overall flow of the CD161 Antibody ecosystem.

Raw material suppliers — provide essential components

Technology providers — develop underlying technologies

OEMs/manufacturers — produce CD161 Antibody products

Distributors/channel partners — facilitate product distribution

Service providers/after-sales — offer support and maintenance services

End users/buyers — purchase and utilize CD161 Antibody products

Regulators/standards bodies — establish guidelines and approvals

In the CD161 Antibody ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact production and distribution. Switching costs and partnerships also play a crucial role, as participants may face significant costs when changing suppliers or partners. Furthermore, the ecosystem's structure and dynamics can differ by region, with varying regulatory requirements and market conditions. A thorough value chain analysis is essential to understanding these complexities and navigating the CD161 Antibody ecosystem effectively.

Recent Industry Insights

The CD161 Antibody industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between major pharmaceutical companies and research institutions have accelerated the development of CD161 antibody-based therapies. Notable mergers and acquisitions have also taken place, expanding the market share of key players. Furthermore, several product launches and technological advancements have improved the efficacy and safety of CD161 antibody treatments.

Additionally, regulatory changes have created a more favorable environment for the growth of the CD161 antibody market. A shift in consumer trends towards personalized medicine has also driven demand for targeted therapies. Funding rounds and expansions have enabled companies to invest in research and development, leading to innovative solutions and a more competitive landscape in the CD161 antibody market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the CD161 Antibody market. The market attractiveness of CD161 Antibody is driven by its potential applications in cancer treatment and autoimmune diseases. The competitive intensity is moderate, with key players investing in research and development to improve treatment outcomes. Looking at the long-term CD161 Antibody market outlook, I foresee significant growth due to increasing demand for targeted therapies. The innovation landscape is characterized by ongoing research into new indications and combination treatments. However, the demand–supply balance may be affected by regulatory approvals and manufacturing capacity. Key risk factors include intense competition, high development costs, and evolving regulatory requirements.

11 items

1. Executive Summary

2. CD161 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD161 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD161 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Immunochemistry (IHC)

6.1.2. Immunofluorescence (IF)

6.1.3. Immunoprecipitation (IP)

6.1.4. Western Blot (WB)

6.1.5. ELISA

6.1.6. Others

6.2. Global CD161 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal

6.2.2. Polyclonal

6.3. Global CD161 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD161 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD161 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CD161 Antibody Market Competition by Key Manufacturers

8.1. Global CD161 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD161 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BD Biosciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GeneTex

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. RayBiotech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. LifeSpan BioSciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BioLegend

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abeomics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bioss

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novus Biologicals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Tonbo Biosciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio-Rad

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cell Sciences

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Miltenyi Biotec

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. R&D Systems

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BMA Biomedicals

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. AAT Bioquest

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Biobyt

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Jingjie PTM BioLab

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD161 Antibody Market

Figure 4: Global CD161 Antibody Market: Drivers

Figure 5: Global CD161 Antibody Market: Challenges

Figure 6: Global CD161 Antibody Market: Trends

Figure 7: Global CD161 Antibody Market: Opportunity

Figure 8: Global CD161 Antibody Market: Restraint

Figure 9: Global CD161 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global CD161 Antibody Market Value (USD Million) By Region

Figure 15: Global CD161 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global CD161 Antibody Market Value (USD Million) By Region

Figure 23: Global CD161 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global CD161 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD161 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CD161 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global CD161 Antibody Market Value (USD Million) By Region

Table 10: Global CD161 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global CD161 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD161 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD161 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BD Biosciences Basic Information And Sales Area

Table 31: BD Biosciences. Products Portfolio

Table 32: GeneTex Basic Information And Sales Area

Table 33: GeneTex. Products Portfolio

Table 34: RayBiotech Basic Information And Sales Area

Table 35: RayBiotech. Products Portfolio

Table 36: LifeSpan BioSciences Basic Information And Sales Area

Table 37: LifeSpan BioSciences. Products Portfolio

Table 38: BioLegend Basic Information And Sales Area

Table 39: BioLegend. Products Portfolio

Table 40: Abeomics Basic Information And Sales Area

Table 41: Abeomics. Products Portfolio

Table 42: Bioss Basic Information And Sales Area

Table 43: Bioss. Products Portfolio

Table 44: Novus Biologicals Basic Information And Sales Area

Table 45: Novus Biologicals. Products Portfolio

Table 46: Tonbo Biosciences Basic Information And Sales Area

Table 47: Tonbo Biosciences. Products Portfolio

Table 48: Bio-Rad Basic Information And Sales Area

Table 49: Bio-Rad. Products Portfolio

Table 50: Cell Sciences Basic Information And Sales Area

Table 51: Cell Sciences. Products Portfolio

Table 52: Miltenyi Biotec Basic Information And Sales Area

Table 53: Miltenyi Biotec. Products Portfolio

Table 54: R&D Systems Basic Information And Sales Area

Table 55: R&D Systems. Products Portfolio

Table 56: BMA Biomedicals Basic Information And Sales Area

Table 57: BMA Biomedicals. Products Portfolio

Table 58: AAT Bioquest Basic Information And Sales Area

Table 59: AAT Bioquest. Products Portfolio

Table 60: Biobyt Basic Information And Sales Area

Table 61: Biobyt. Products Portfolio

Table 62: Jingjie PTM BioLab Basic Information And Sales Area

Table 63: Jingjie PTM BioLab. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global CD161 Antibody Market Value (USD Million) By Region

Table 69: Global CD161 Antibody Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

CD161 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD Biosciences; GeneTex; RayBiotech; LifeSpan BioSciences; BioLegend; Abeomics; Bioss; Novus Biologicals; Tonbo Biosciences; Bio-Rad; Cell Sciences; Miltenyi Biotec; R&D Systems; BMA Biomedicals; AAT Bioquest; Biobyt; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Stringent regulatory frameworks and the requirement for extended approval processes can delay the launch of new CD161 Antibody products, impacting the overall growth forecast of the market.

Opportunities2 items

Emerging markets and partnerships with local players can provide access to new customer bases, contributing to the growth of the CD161 Antibody market size and its global reach.

Challenges2 items

Ensuring the quality and efficacy of CD161 Antibody products while maintaining cost-effectiveness is a critical challenge that manufacturers must address to sustain growth in the market.

Market Segmentation

Loading chart…

CD161 Antibody Segmentation Breakdown10 items

Application

Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Types

Monoclonal

Polyclonal

Regional Insights

Loading chart…

Competitive Landscape

BD Biosciences: regional expansion

GeneTex: innovation pipeline

RayBiotech: premium pricing

LifeSpan BioSciences: local manufacturing

BioLegend: OEM tie-ups

Abeomics: vertical integration

Key CD161 Antibody Companies17 items

BD Biosciences

GeneTex

RayBiotech

LifeSpan BioSciences

BioLegend

Abeomics

Bioss

Novus Biologicals

Tonbo Biosciences

Bio-Rad

Cell Sciences

Miltenyi Biotec

R&D Systems

BMA Biomedicals

AAT Bioquest

Biobyt

Jingjie PTM BioLab

Market Ecosystem

Raw material suppliers — provide essential components

Technology providers — develop underlying technologies

OEMs/manufacturers — produce CD161 Antibody products

Distributors/channel partners — facilitate product distribution

Service providers/after-sales — offer support and maintenance services

End users/buyers — purchase and utilize CD161 Antibody products

Regulators/standards bodies — establish guidelines and approvals

Recent Industry Insights

Analyst Overview

Table of Contents